Cann Group to acquire Satipharm from Harvest One Cannabis

Cann Group to acquire Satipharm from Harvest One Cannabis

[videojs_hls url=’//du7x25at22z7c.cloudfront.net/317894/index_HLSv3.m3u8′ poster=’http://www.finnewsnetwork.com.au/newssystem/2021/Headlines01_360_210215.jpg’]

 

Medicinal cannabis producer Cann Group (ASX:CAN) has sealed a deal to acquire Satipharm from Canadian-domiciled Harvest One Cannabis (CVE:HVT).

The acquisition will provide the buyer an exclusive license to develop and market the propertary Gelpell delivery system for cannabinoids and accelerate the development of other novel THC-based medicines. Market researchers have tipped the acquisition to widen Cann (ASX:CAN)’s market reach, considering existing commercial supply agreements with distribution channels in the UK, Ireland and Eastern Europe.

Shares in Cann Group (ASX:CAN) are trading 1.3 per cent higher at $0.78.

Copyright 2021 – Finance News Network


Source: Finance News Network

Share this post